PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1741307
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1741307
Nausea Medicine Market is estimated to be valued at USD 3.17 Bn in 2025 and is expected to reach USD 4.86 Bn by 2032, growing at a compound annual growth rate (CAGR) of 6.3% from 2025 to 2032.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2024 | Market Size in 2025: | USD 3.17 Bn |
Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
Forecast Period 2025 to 2032 CAGR: | 6.30% | 2032 Value Projection: | USD 4.86 Bn |
Nausea is an unsettling sensation that is often accompanied by the urge to vomit, which can significantly disrupt a daily life. Nausea medicine which is a vital aspect of modern healthcare, aims to alleviate the distressing symptom and improve overall well-being. The medicine that is designed to target body's specific receptors is responsible for nausea and vomiting. These medications come in various forms, including pills, liquids and patches. By effectively blocking the receptors, nausea medicine provides the needed relief to patients who are suffering from motion sickness, chemotherapy-included nausea, pregnancy-related discomfort, and other related conditions. This introduction delves into the importance of these medicines in enhancing quality of life for individuals plagued by nauseous episodes.
Increasing prevalence of nausea, advancements in drug formulations and increasing geriatric population, increasing research and development activities is anticipated to drive growth of the global nausea medicine market over the forecast period. Moreover, growing awareness and diagnosis is also expected to boost the growth of the global nausea medicine market over the forecast period. Development of targeted therapies, expansion into emerging markets, combination therapies and non-pharmacological interventions are expected to create growth opportunities for the global nausea medicine market during the forecast period.For instance, in May 2023, Vanda Pharmaceuticals Inc., a worldwide biopharmaceutical company, revealed the results of its Phase III research of tradipitant in motion sickness, thereby confirming the previously published findings that tradipitant is beneficial in the prevention of motion sickness vomiting. The Phase III study was carried out on boats in U.S. coastal waters under real-world situations.
However, adverse effects and safety concerns, high cost of nausea medicines, lack of targeted therapies for specific causes and limited efficiency in some cases are expected to hamper growth of the global nausea medicine market over the forecast period.